Compare Enveric Biosciences Inc (ENVB) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.47 (market cap $27.76B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 4149.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 30,088,564). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| ENVB | LQD | |
|---|---|---|
Market Cap | $6.69M | $27.76B |
Volume | 41,141 | 30,088,564 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $112.91 |
52-Week Low | $1.27 | $101.83 |
Typical Hold Time | 14 Days | 125 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
LQD trades at $102.12, down 0.02% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The ETF faces headwinds from rising bond yields and a significant 53.1% increase in short interest reported as of September 15, 2026. Recent dividends include $0.44 and $0.46 payouts scheduled through October 2026, providing income support.
Outlook remains cautious due to persistent bond market volatility and higher interest rates, which pressure corporate bond ETFs. Investment opportunities lie in the 4.8% yield and high-quality portfolio, but risks include further yield spikes and economic slowdowns affecting credit quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
